Clinical Trial Update: Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluates nerve growth factor delivered via MPC nanocapsules for amyotrophic lateral sclerosis, and the study is currently not recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Nerve Growth Factor encapsulated with MPC nanocapsules

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: Amyotrophic Lateral Sclerosis | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING